CureVac (NASDAQ:CVAC) Shares Gap Down – Here’s What Happened

Posted by Paula Ricardo on Jan 10th, 2025

CureVac (NASDAQ:CVAC – Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $4.68, but opened at $4.36. CureVac shares last traded at $3.97, with a volume of 913,131 shares.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research note on Monday, September 16th.

Get Our Latest Stock Report on CVAC

CureVac Stock Performance

The stock has a market capitalization of $947.01 million, a price-to-earnings ratio of 7.69, a price-to-earnings-growth ratio of 0.24 and a beta of 2.50. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a fifty day moving average of $3.06 and a two-hundred day moving average of $3.14.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Private Advisor Group LLC bought a new position in shares of CureVac in the third quarter worth about $30,000. International Assets Investment Management LLC acquired a new stake in CureVac in the 3rd quarter valued at approximately $35,000. Integrated Wealth Concepts LLC bought a new position in CureVac in the 3rd quarter worth approximately $35,000. Bank of New York Mellon Corp acquired a new position in shares of CureVac during the second quarter worth approximately $54,000. Finally, Barclays PLC bought a new stake in shares of CureVac in the third quarter valued at approximately $67,000. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

(Get Free Report)

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.